Skip to main content

Branded

  • Breast cancer, hepatitis C drugs get FDA approval

    SILVER SPRING, Md. — The Food and Drug Administration this week has approved two new drugs, Gilead’s hepatitis C treatment Vosevi and Puma Biotechnology’s breast cancer drug Nerlynx. 
     

  • CVS Health pledges $250K for opioid abuse treatment center near HQ

    WOONSOCKET, R.I. — CVS Health is teaming up with Rhode Island Gov. Gina Raimondo to help open an opioid Center of Excellence here, where the company has its headquarters, in an effort expand access to medication-assisted treatment. The company has committed $250,000 to the Community Care Alliance to open and operate the Woonsocket Center.

  • FDA approves Janssen’s plaque psoriasis drug Tremfya

    SILVER SPRING, Md. — The Food and Drug Adminisration has approved Janssen Biotech’s new treatment for plaque psoriasis, the company announced Thursday. Tremfya (guselkumab) is the first drug to be approved that selectively blocks a key plaque psoriasis cytokine, the company said.

  • PhRMA adds 2 VPs

    WASHINGTON — The Pharmaceutical Research and Manufacturers of America this week announced two new additions to its ranks. The company has added Mike Hotra as VP of its public affairs team, and Ken McKay as VP state government affairs. 
     

  • FDA approves first new sickle cell drug in almost 20 years

    SILVER SPRING, Md. — The Food and Drug Administration on Friday approved a new treatment for severe complications from sickle cell disease — the first in nearly 20 years for the blood disorder. Endari (L-glutamine oral powder) was developed and is manufactured by Emmaus Life Sciences

  • Senators urge Mattis to implement TRICARE pharmacy pilot

    WASHINGTON — Twenty-one senators recently sent a letter to Defense Sec. James Mattis, encouraging him to implement the TRICARE Acqisition Cost Parity Pilot Program for Retail Pharmacy.

  • Endo to divest Mexican generics arm Grupo Farmcéutico SOMAR

    DUBLIN — Endo will be selling its Mexico City-based Grupo Farmcéuitco SOMAR division to Advent International, the company announced Wednesday. The deal will see the Mexican private generics leader sold to Advent for roughly $124 million.

  • FDA approves new indication for Amgen’s Vectibix

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new indication for Amgen’s Vectibix (panitumumab). The biologic has been approved to treat patients with wild-type RAS metastatic colorectal cancer, the company announced Thursday.

X
This ad will auto-close in 10 seconds